Mid-Size Pharmaceutical Market Analysis

The Mid-Size Pharmaceutical Market is projected to reach US$ 1,224.039 billion by 2031 from US$ 732.02 billion in 2023, registering a CAGR of 8.9% during 2023 to 2031. This steady expansion reflects the increasing global demand for innovative therapies, the rising burden of chronic diseases, and a growing aging population. Greater focus on research and development remains a defining trend as mid-sized pharmaceutical companies strengthen their competitive positioning through product innovation and strategic collaborations.

The growth of the mid-size pharmaceutical market is primarily driven by demographic and epidemiological shifts. The rising geriatric population worldwide has significantly increased the incidence of chronic disorders such as cardiovascular diseases, diabetes, cancer, and arthritis. According to the World Health Organization, the prevalence of chronic diseases is projected to rise by 57% by 2026, with developing countries expected to experience the most substantial impact due to rapid population growth and urbanization.

Urbanization has led to lifestyle changes characterized by sedentary habits and poor dietary patterns, contributing to obesity and metabolic disorders. Diabetes, in particular, represents one of the most pressing global health challenges. The International Diabetes Federation reported that approximately 46 million people in North America were living with diabetes in 2019, and this number is projected to reach 62 million by 2045, reflecting a 35% increase. Such trends underscore the expanding therapeutic demand that mid-sized pharmaceutical firms are well positioned to address.

Pandemics have also highlighted the need for resilient healthcare systems capable of managing widespread outbreaks while continuing chronic disease care. This has reinforced the importance of diversified drug portfolios and agile manufacturing capabilities among mid-sized pharmaceutical companies.

Download Free Sample PDF- https://www.theinsightpartners.com/sample/TIPRE00018321 

Mid-Size Pharmaceutical Market Overview

The aging population is a central growth catalyst. In the United States, individuals aged 65 and older are expected to increase from 52 million in 2018 to approximately 95 million by 2060, according to the US Census Bureau. This demographic shift is directly associated with higher incidences of dementia, heart disease, type 2 diabetes, arthritis, and cancer. The Centers for Disease Control and Prevention states that nearly six in ten adults in the US suffer from at least one chronic disease, and four in ten have two or more conditions. These factors are significantly increasing healthcare expenditures and pharmaceutical demand.

Mid-sized pharmaceutical companies are leveraging their operational flexibility to respond quickly to evolving patient needs. Their ability to balance innovation with cost efficiency positions them uniquely between large multinational corporations and smaller biotech firms.

Market Drivers and Opportunities

Increasing Product Approvals and Launches

The mid-size pharmaceutical market is characterized by continuous product innovation and regulatory approvals. Companies frequently pursue strategies such as product launches, regional expansion, and technology upgrades to enhance market share. For example, Eisai Co., Ltd. introduced MOVICOL HD, an advanced formulation for chronic constipation treatment, under a co-promotion agreement with EA Pharma. Similarly, Sun Pharmaceutical Industries Ltd. received final approval from the US FDA for its generic Mesalamine Extended-Release Capsules, referencing Pentasa as the branded product. Such approvals reinforce revenue streams and strengthen competitive positioning.

Rising Number of Healthcare Start-ups

Technological advancements, including artificial intelligence and big data analytics, are reshaping pharmaceutical research and development. The emergence of healthcare start-ups has introduced innovative drug discovery models, digital therapeutics, and advanced manufacturing technologies. Companies such as Alpha Zyme, founded in 2018, demonstrate how new entrants contribute to innovation by focusing on enzyme development and strategic partnerships. The increasing collaboration between start-ups and established mid-sized pharmaceutical firms creates new growth avenues and accelerates time to market.

Segmentation Analysis

By type, the market is divided into prescription and over the counter products, with over the counter drugs holding the largest share in 2023 due to increased consumer awareness and accessibility.

By drug development type, the market is segmented into in-house and outsource models. Outsourcing accounted for a significant share as companies seek cost optimization and specialized expertise.

In terms of formulation, tablets and capsules dominated the market, followed by injectables and sprays.

By therapy class, diabetes represented the largest segment in 2023, reflecting the growing global burden of metabolic disorders.

Regional Insights

North America holds a dominant position, with the US representing the largest market. Growth is fueled by demographic expansion, high chronic disease prevalence, and advanced healthcare infrastructure. Europe follows with strong regulatory frameworks and research initiatives. Asia Pacific is expected to experience substantial growth due to expanding healthcare access and increasing pharmaceutical manufacturing capabilities in countries such as China and India.

Key Market Players

• DAIICHI SANKYO COMPANY LIMITED

• Eisai Co., Ltd.

• Regeneron Pharmaceuticals, Inc.

• Bausch Health Companies Inc.

• Sun Pharmaceutical Industries Ltd.

• Alexion Pharmaceuticals, Inc.

• Mallinckrodt

• Endo Pharmaceuticals Inc.

• Les Laboratoires Servier

• UCB S.A.

These players focus on acquisitions, partnerships, and R&D investments to enhance product portfolios and global reach. For instance, Regeneron Pharmaceuticals announced the acquisition of Checkmate Pharmaceuticals in an all-cash transaction valued at approximately US$ 250 million, strengthening its oncology pipeline.

Future Outlook

The mid-size pharmaceutical market is expected to witness sustained growth through 2031, supported by increasing chronic disease prevalence, demographic aging, and continuous product innovation. Companies that invest in digital transformation, precision medicine, and strategic collaborations will likely achieve competitive advantages. As healthcare systems evolve toward value-based care models, mid-sized pharmaceutical firms with flexible operations and diversified portfolios will play a crucial role in delivering accessible and cost-effective therapies worldwide.